| Bioequivalence Study of Suprimun/Micoflavin/Myclausen in 44 healthy volunteers. |
 |
A Four-Period, Two-Sequence, Replicate Crossover,
Open-Label, Single-Dose, Fasting, Bioequivalence Study of
Mycophenolate Mofetil* 500 mg Tablets (Laboratorios Clausen S.A.)
versus CellCept 500 mg Tablets (Roche) in Normal, Healthy, Non-
Smoking Male Subjects.
*Suprimun/Micoflavin in Latinamerica
Myclausen in the European Union
01/02/2011
|
|
|
| Evaluation of Filgen JP. |
 |
Evaluation of Haematopoietic stem cells mobilization for autologous bone marrow transplantation in hematological malignancies and solid tumors with Filgen JP (Clausen Filgrastim). Experience of one center (Maciel Hospital, Montevideo Uruguay).
Dicember 2006
Only abstract in English |
|
|
|
|
| Evaluation of Bioequivalence of Mycophenolate Mofetil (12 healthy volunteers). |
 |
Evaluation of Bioequivalence of a new Mycophenolate Mofetil pharmaceutical formulation
February 2006
Only abstract in English
|
|
|
| Evaluation of Eritrogen. |
 |
Evaluation of Eritrogen (Clausen alfa Erythropoietin - Iclos Erythropoietin) in the treatment of anemia in patients with chronic renal failure in dialysis. Uruguay 2006.
October 2007
Only abstract in English |
|
|
|
|
| Use of Avirostat and INF. |
 |
Use and tolerance of Avirostat (alfa-2a interferon) and INF (alfa-2b interferon) in solid tumors, a retrospective descriptive study. National Cancer Institute experience (Montevideo-Uruguay).
Diciembre 2007
Only abstract in English
|
|
|
| Evaluation of Filgen JP. |
 |
Evaluation of Filgen JP (Filgrastim Clausen) for the prevention or treatment of neutropenia induced by chemotherapy in solid tumors treatment.
Diciembre 2007
Only abstract in English |
|
|
|
|
| Evaluation of Bioequivalence of Mycophenolate Mofetil (24 healthy volunteers). |
 |
Bioequivalence Evaluation of Mycophenolate Mofetil 500 mg Tablets [Suprimun® 500mg (Clausen) vs. CellCept® 500mg (Roche)] in Healthy Volunteers.
June 2008
|
|
|
